Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with PharmaEssentia Corp.’s R&D center in Boston, United States. The collaboration will fully utilize Nona Bio’s Harbor Mice whole human transgenic mouse platform technology for biomedicine research and development, marking a significant step in advancing therapeutic solutions.
Harnessing HCAb Technology for Next-Generation Antibodies
Harbour/Nano’s HCAb technology enables the development of next-generation, wholly human heavy-chain antibodies that are half the size of conventional IgG antibodies. This innovative platform has the potential to revolutionize the development of multiple therapeutic antibodies, including monodomain antibodies, bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), chimeric antibody receptor (CAR)-T cell therapies, and other VH monodomain derivatives.
Harbor Mice Platform Attracts Global Partnerships
The Harbor Mice platform has garnered significant interest from a range of companies, leading to partnerships with industry leaders such as BeiGene, WuXi Bio, Chia Tai TianQing, Tot Bio, Mount Sinai Medical Center, Vir Biotechnology, and AbbVie. These collaborations underscore the global recognition of the platform’s potential to drive forward biomedical research and development.-Fineline Info & Tech
